



HAL
open science

Perioperative Management of Heart Transplantation: A Clinical Review

Nicolas Nessler, Alexandre Mansour, Bernard Cholley, Guillaume Coutance, Adrien Bouglé

► **To cite this version:**

Nicolas Nessler, Alexandre Mansour, Bernard Cholley, Guillaume Coutance, Adrien Bouglé. Perioperative Management of Heart Transplantation: A Clinical Review. *Anesthesiology*, 2023, 139 (4), pp.493-510. 10.1097/ALN.0000000000004627. hal-04164811

HAL Id: hal-04164811

<https://hal.sorbonne-universite.fr/hal-04164811v1>

Submitted on 18 Jul 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title Page

1. Article Title: Perioperative Management of Heart Transplantation: a Clinical Review

2. Author information:

Nicolas NESSELER, M.D., Ph.D., Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, France; Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), F35000 Rennes, France. Univ Rennes, CHU de Rennes, Inra, Inserm, Institut NUMECAN – UMR_A 1341, UMR_S 1241, F-35000 Rennes, France

Alexandre MANSOUR, M.D., Ph.D., Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, France; Univ Rennes, CHU Rennes, Inserm, IRSET, UMR_S 1085, F35000 Rennes, France.

Bernard CHOLLEY, M.D., Ph.D., Department of Anesthesiology and Intensive Care Medicine, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris, France; Université Paris Cité, Inserm UMR_S 1140, F-75006 Paris, France

Guillaume COUTANCE, M.D., Ph.D., Sorbonne University, Assistance Publique – Hôpitaux de Paris, Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié-Salpêtrière Hospital, Paris, France

Adrien BOUGLÉ, M.D., Ph.D., Sorbonne University, GRC 29, Assistance Publique – Hôpitaux de Paris, Department of Anesthesiology and Critical Care, Cardiology Institute, Pitié-Salpêtrière Hospital, Paris, France

3. Corresponding Author:

Dr Adrien BOUGLÉ, Sorbonne University, GRC 29, Assistance Publique – Hôpitaux de Paris, Department of Anesthesiology and Critical Care, Cardiology Institute, Pitié-Salpêtrière Hospital, Paris, France

Tel.: +33 1 42 16 29 91 E-mail: adrien.bougle@aphp.fr

4. Clinical trial number and registry URL: None

5. Prior Presentations: None.

6. Acknowledgments: None

7. Word and Element Counts:

Manuscript: 3850

Number of figures: 1

Number of tables: 4

8. Abbreviated Title (Running Head): Perioperative Management of Heart Transplantation

9. Summary Statement: In this clinical review, the authors summarized the perioperative management of heart transplant patients with a focus on hemodynamics, immunosuppressive strategies, hemostasis and hémorrhage, and the prevention and treatment of infectious complications.

10. Funding Statement:

No funding.

11. Conflicts of Interest:

Nicolas Nessler: declares no competing interests

Alexandre Mansour: received payments made to his institution from i-SEP for consulting fees, and from LFB, Aguetant and Pfizer for lecture fees.

Bernard Cholley: received payments from Orion Pharma, Nordic Pharma, Edwards Life Sciences, and AOP Orphan for participation to advisory boards and lectures at industry symposia.

Guillaume Coutance: declares no competing interests

Adrien Bouglé: received payments from Fresenius and LFB for lecture fees.

Introduction

Heart transplantation remains the treatment of choice for patients with end-stage heart failure allowing high-survival rates and improved quality of life¹. Worldwide, more than 6000 heart transplantations are performed annually, with one-year post-transplant survival around 85% and median survival now exceeding 12 years². The progressive improvement in post-transplant outcome that has been observed over these years is mostly driven by a dramatic drop in the early post-transplant mortality². However, the first weeks following heart transplantation remain critical with an 8% 1-month mortality in contemporary cohorts². The perioperative period remains at very high risk due to the increasing proportion of candidates bridged to transplant with durable mechanical circulatory supports and an increasing number of sensitized patients^{3,4}. In addition, the prioritization of high-risk candidates on ECMO support and the broader eligibility for both recipient- and donor-related risk factors of primary graft dysfunction (older age, comorbidities) also contribute to increase the challenges of the perioperative period^{2,5}. The role of the cardiothoracic anesthesiologist-intensivist in the early management of heart transplant recipients is crucial both during surgery and in the ICU⁶. Guidelines focused on the perioperative management of heart transplant recipients are still lacking and the area of knowledge required is vast. This includes the management of hemodynamic instability, transfusion and hemostatic disorders, immunosuppression, infectious complications (prevention and treatment) in addition to acute kidney injury and renal replacement therapy. This review aims at summarizing the latest knowledge in the field of perioperative management of heart transplant recipients in order to guide cardiothoracic anesthesiologist-intensivists.

Hemodynamic management

Vasoplegia

Defining vasoplegia

A refractory vasoplegic syndrome (a persistent low vascular resistance requiring intravenous vasopressors) is observed in 11-60% of heart transplantation patients^{7,8}. There is currently no standard consensus on the definition of vasoplegic syndrome after cardiac surgery or more specifically after heart transplantation, but hypotension occurring within 24 h of heart transplantation with a cardiac index (CI) greater than 2.2 L/kg/m² and a systemic vascular resistance of less than 800 dyne-s/cm⁵ is generally considered characteristic of this situation^{7,9}. The pathophysiology of vasoplegic syndrome remains poorly understood, but it could be associated with cytokine release, adrenergic receptor desensitization, increased nitric oxide synthesis, relative deficiency of vasopressin, activation of ATP-sensitive potassium channels, vascular smooth muscle cell membrane hyperpolarization, dysfunction of the renin-angiotensin system, and endothelial glycocalyx alteration¹⁰.

Risk factors

Age, history of thyroid disease or chronic kidney disease, ventricular-assist device prior to transplant, duration of cardiopulmonary bypass and intra operative blood products are associated with this condition^{8,11,12}. Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers is associated with vasoplegia after cardiac surgery¹³, although this is less well documented after heart transplantation⁸. Nevertheless, the presence of a vasoplegic syndrome may be associated with an unfavorable prognosis in heart transplantation patients¹⁴, and the consequences of the vasoplegia do not appear to differ after heart transplantation and after standard cardiac surgery¹⁵.

Management of vasoplegia

As highlighted in the recent guidelines of the International Society for Heart and Lung Transplantation, the first-line choice in the treatment of vasoplegia is norepinephrine¹⁶ (see figure, Supplemental Digital Content 1). However, the management of post heart transplantation vasoplegia is most often extrapolated from the literature related to this condition following standard cardiac surgery, due to the lack of specific data. In a recent Brazilian single center study, Hajjar et al. randomized 330 patients with vasoplegic shock after cardiac surgery to receive vasopressin or norepinephrine¹⁷. Mortality or severe complications occurred in 32% of patients receiving vasopressin, compared with 49% receiving norepinephrine, but the extrapolation of these findings has been questioned. Moreover, acute renal failure occurred in only 10.3% of patients receiving vasopressin, compared with 35.8% of patients receiving norepinephrine¹⁷. In heart transplantation patients with vasoplegia syndrome, vasopressin was shown to decrease norepinephrine requirements, but the level of evidence remains low¹⁸. Similarly, the use of methylene blue, hydroxocobalamin or angiotensin II could be of interest in this population but, up to now, efficacy of these therapies has only been substantiated by cases reports^{10,19-23}.

Primary graft dysfunction

Defining primary graft dysfunction

The International Society of Heart and Lung Transplant defined primary graft dysfunction after heart transplantation as a failure of the transplanted heart, necessitating high doses of catecholamines and/or temporary mechanical circulatory support to achieve an adequate cardiac index in the recipient, and diagnosed within 24 hours of completion of surgery in the absence of a discernible alternate cause such as hyper acute rejection, pulmonary hypertension or surgical complications^{24,25}. Primary graft dysfunction can be further characterized as predominantly left-sided or right-sided, as well as mild, moderate, or severe, depending on the level of cardiac dysfunction and the extent of inotrope and mechanical support required (Table 1). The most recent data suggest an incidence of 10% to 36% with severe primary graft dysfunction occurring in 8 to 18%

of heart transplantation patients. Primary graft dysfunction is associated with increased 30-day and one-year mortality²⁵.

Risk factors

The risk factors for primary graft dysfunction include factors related to the donor, the recipient, and the surgical procedure itself (Table 2). The RADIAL score was developed from a cohort of 621 heart transplantation patients in which 6 risk factors were identified using multivariable analysis: 1) recipient risk factors include: right atrial pressure ≥ 10 mm Hg, age ≥ 60 years, diabetes mellitus, dependence towards inotropes, 2) donor risk factors: age ≥ 30 years, and length of ischemic time ≥ 240 minutes²⁶. The RADIAL score allows heart transplantation patients to be stratified into groups with an incremental incidence of primary graft dysfunction²⁷. In patients bridged to heart transplantation with continuous-flow left ventricular assist devices, the RADIAL score did not accurately predict severe primary graft dysfunction. In this group, the risk factors for primary graft dysfunction included: mechanical support duration >1 -year, elevated pre-heart transplantation creatinine plasma levels, elevated central venous pressure/pulmonary capillary wedge pressure ratio, and use of amiodarone before heart transplantation²⁸.

Management of primary graft dysfunction

Despite the lack of high-level evidence supporting their efficacy, inotropic drugs and vasopressors (including dobutamine, dopamine, milrinone, epinephrine, and norepinephrine) remain the first line treatment for primary graft dysfunction. These medications may potentially be combined with vasopressin and inhaled nitric oxide⁸ (see figure, Supplemental Digital Content 1). The use of milrinone as a bridge to transplantation has been reported in a few cohort studies, but the data regarding the treatment of primary graft dysfunction using this medication is extremely limited^{29,30}. Weis et al. assessed the effect of levosimendan in twelve heart transplantation patients with primary graft dysfunction, with good results on hemodynamic parameters such as cardiac index, mean

arterial pressure, or mean pulmonary artery pressure³¹. In this cohort of patients with primary graft dysfunction, survival at day-30 was 93%. When cardiac output remains inadequate despite high doses of inotropes and/or vasopressors, the use of temporary mechanical circulatory support is needed to provide systemic perfusion and oxygenation, allowing the graft to recover and maintaining the other organs. For patients needing a temporary mechanical circulatory support, veno arterial ECMO seems to be associated with shorter assistance duration, lower incidence of major bleeding, of renal failure requiring renal replacement therapy, and reduced mortality compared with patients supported with a continuous-flow external ventricular assist device³². The ideal timing for ECMO implantation in patients with primary graft dysfunction is not known. However, as with the timing for ECMO implantation in post cardiectomy cardiogenic shock, it can be assumed that early implantation is beneficial. Thus, in a cohort of 347 patients assisted with post cardiectomy veno arterial ECMO, including 59 primary graft dysfunction patients, postoperative implantation of veno arterial ECMO was independently associated with an increased risk of Kidney Disease Improving Global Outcomes stage 3 acute kidney injury³³. In a retrospective study involving 135 primary graft dysfunction patients including 66 assisted with veno arterial ECMO, delayed initiation of veno arterial ECMO was independently associated with in-hospital mortality³⁴. Thus, veno arterial ECMO implantation appears to be an efficient strategy for the management of severe primary graft dysfunction, in spite of a significant impact on long-term quality of life³⁵. Finally, although there is data pointing to a beneficial effect of left ventricle unloading in patients assisted by veno arterial ECMO, there is little specific evidence in transplant patients³⁶. Indeed, in a recent study from the Extracorporeal Life Support Organization registry on the association between left ventricle unloading and in-hospital mortality, transplantation was an exclusion criterion³⁶.

Right heart failure / Pulmonary Hypertension

Right heart failure remains a frequent and potentially severe complication after heart transplantation and contributes significantly to morbidity and mortality. When a discernible cause

can be identified, right heart failure is related to a secondary graft dysfunction. Usual etiologies include hyper acute rejection (see dedicated paragraph), known surgical complication, or pulmonary hypertension. As the presence of pre-transplant pulmonary hypertension in heart recipients increases the risk of post-transplant right heart failure, the selection of transplant recipients and their pre-transplant hemodynamic optimization is essential. A single-center retrospective study reported an incidence of 5.9% for severe right heart failure after heart transplantation, while increased pulmonary capillary wedge pressure and mean pulmonary arterial pressure were identified as risk factors³⁷. The International Society for Heart and Lung Transplantation suggests that a pulmonary vasodilator challenge with inhaled (nitric oxide or prostacyclins) or intravenous (nitroglycerin or nitroprusside) vasoactive agents should be administered when the systolic pulmonary artery pressure is ≥ 50 mmHg and when the transpulmonary gradient is ≥ 15 mmHg or the pulmonary vascular resistance is > 3 Wood units. Meanwhile, systolic arterial blood pressure should be maintained above 85 mmHg. Although the right and left filling pressures decrease within weeks following heart transplantation, an elevated mPAP after transplantation is an independent prognostic factor for long-term mortality^{38,39}.

The management of right heart failure relies on the preservation of coronary perfusion through the maintenance of an adequate mean arterial pressure using norepinephrine infusion, optimization of the right ventricle preload with careful monitoring to avoid congestion, reduction of the right ventricle afterload by decreasing pulmonary vascular resistance and limitation of pulmonary vasoconstriction through ventilator settings (avoiding hypoxia and hypercarbia)⁴⁰ (see figure, Supplemental Digital Content 1). Inhaled nitric oxide is unique in that it allows selective pulmonary vasodilatation and is effective in improving stroke volume as a result of right ventricle afterload reduction⁴¹. However, there is currently no clear evidence that this medication may improve long-term outcome in patients and the cost/benefit ratio is questioned⁴². Finally, it was recently suggested, in a retrospective cohort of cardiac surgical patients with pulmonary hypertension or

right ventricular failure, that the combination of inhaled milrinone and epoprostenol was associated with beneficial effects on hemodynamics⁴³.

The severe forms of primary graft dysfunction are traditionally managed with veno arterial ECMO, but up to 45% of patients with primary graft dysfunction have isolated right ventricular dysfunction²⁷. In these patients, percutaneous right ventricular support, for example through the Protek Duo cannula or with the Abiomed Impella RP device, could be particularly useful, allowing mechanical support of the right ventricle without the detrimental effects of veno arterial ECMO (non-physiological circulation with reduced pulmonary flow, risk of intravascular pulmonary thrombosis, increased left ventricular afterload)^{44,45}.

Arrhythmias

The mechanisms for arrhythmogenesis in heart transplant patients are related to several factors including: surgical technique, graft ischemia duration, autonomic denervation, immune rejection, cardiac allograft vasculopathy, and graft dysfunction. The loss of parasympathetic input from the vagus nerve results in a higher resting heart rate for transplant patients (90-100 bpm) and a significantly reduced heart rate variability. Graft ischemia exceeding 240 minutes and the bi-atrial surgical technique are associated with increased rates of post-operative atrial fibrillation. Atrial fibrillation, atrial flutter, and supra ventricular tachycardia are the most common post-transplant arrhythmias and are associated with decreased long-term survival^{46,47}. Despite their frequency, atrial arrhythmias occur in heart transplant recipients at a much lower rate (2-4%) than in other post cardiac surgery patients (overall incidence of 26.7%, from 22.9% for CABG to 45.2% for combined procedures^{46,48}). The majority of atrial fibrillation episodes occur within two weeks of transplantation, whereas atrial flutter most commonly presents after the first two weeks. Atrial fibrillation and flutter may be associated with acute rejection and/or cardiac allograft vasculopathy, particularly when arrhythmias persist beyond the post-operative period^{46,47}. Ventricular arrhythmias and sudden cardiac arrest represent 10% of deaths after heart transplantation, with an incidence of 1.30 per 100

person-years^{49,50}. Treated rejection and cardiac allograft vasculopathy were described as risk factors for sudden cardiac death in heart transplant patients⁵¹. The management of atrial fibrillation after heart transplantation is similar to that of other cardiac surgery patients. A treatment strategy of rate versus rhythm control is determined by the presence of symptoms and the effect of atrial fibrillation on systolic function. Rate control may be achieved with β -blockers, with short half-life drugs being preferred at the onset of treatment in this setting to ensure tolerance. Rhythm control may consist in electrical or pharmacological cardioversion⁵². It should be remembered, however, that treatment of the recipient with amiodarone before heart transplantation is a well-established factor for primary graft dysfunction^{45,53,54}. Finally, as these patients are frequently on inotropes, it may be strategic to decrease the inotropes and to look for other pharmacologic methods for rate or rhythm control. There are no specific guidelines for anticoagulation after heart transplantation, and a decision should be made after considering the CHA₂DS₂-VASc score according to current guidelines⁵⁵. Sinus node dysfunction and atrioventricular block requiring pacemaker implantation are present in 2 to 15% of heart transplant patients⁵⁶⁻⁵⁸. In addition to the bi-atrial surgical technique, risk factors for early pacemaker implantation (less than 3 months) are donor age, ischemic time, cellular rejection and amiodarone use before heart transplantation⁵⁹. Late pacemaker implantation (more than 3 months) risk factors include donor age and cardiac allograft vasculopathy⁶⁰.

Tricuspid regurgitation

Tricuspid regurgitation is the most common valvular abnormality after heart transplantation (19-84%), and has been associated with increased morbidity and mortality^{61,62}. The risk of mortality is greater in case of tricuspid regurgitation due to primary graft dysfunction or rejection⁶³. Therefore, if the effects of sub-clinical tricuspid regurgitation remain controversial, the more severe forms could be associated with chronic fluid congestion, lower extremity edema, liver congestion and finally renal failure⁶⁴.

Whether there may be other factors that could be responsible for a functional tricuspid regurgitation (allograft rejection, pre-operative abnormal transpulmonary gradient and vascular resistance), the main risk factor seems to be the bi-atrial surgical technique⁶⁵. Hence, Aziz et al. observed a higher incidence of tricuspid regurgitation among patients who underwent bi-atrial surgical technique versus patients who underwent a bi-caval approach (41% at 1 month, 52% at 24 months vs. 15% at 1 month and 30% at 24 months)⁶⁶. Tricuspid regurgitation can also be the consequence of the anatomic disruption of the sub-valvular apparatus. Specifically, endomyocardial biopsy, performed to detect allograft rejection, is a procedure particularly at risk of creating valvular lesions. Although the majority of patients are asymptomatic, moderate to severe tricuspid regurgitation can induce progressive right ventricle cavity enlargement, elevated right-side pressures and eventually symptoms of right heart failure. Diuretics remain the cornerstone treatment for patients with tricuspid regurgitation. However, a surgical intervention could be indicated in refractory cases to prevent ventricular failure and the systemic consequences of severe tricuspid regurgitation⁶⁷.

Perioperative management of immunosuppression

Allograft rejection remains an important cause of graft dysfunction, patient mortality and morbidity after heart transplantation⁶⁸. The immunosuppressive regimen must balance the risk between allograft rejection and the complications of over-immunosuppression, particularly infectious complications occurring early after heart transplantation.

Induction therapy

The principle of an induction therapy is to induce a profound and rapid immunosuppression to lower the risk of rejection. Three approaches are widely used (sorted by the level of immunosuppression required): (i) no induction therapy, (ii) non-depletive monoclonal induction using IL-2 receptor antagonists and (iii) polyclonal induction with anti-thymocyte globulins (T-cell depletion therapy).

The practice is variable across centers and countries⁶⁸. No study ever proved a survival benefit of one strategy over another at the population level⁶⁹. The benefit-risk ratio of each approach should be discussed for every patient at the time of listing. Table 3 summarizes the doses, side effects and monitoring of each drug.

Perioperative management of allosensitization

Allosensitization represents a major barrier to heart transplantation. The presence of antibodies to human leukocyte antigens (HLA) is associated with increased risk of waitlist mortality. The proportion of allosensitized patients awaiting heart transplantation continues to increase, possibly due to the increasing exposition to procedures prior to transplant, including durable mechanical circulatory support, homografts, and blood products⁴.

Virtual crossmatches at the time of organ proposal (i.e., the analysis of the immunological compatibility of the donor and the recipient: comparison of anti-HLA antibody developed by the recipient to the HLA antigens of the donor), allow an accurate and early evaluation of the immunological risk of rejection. The exclusion of grafts from donors with HLA antigens against which the recipient has developed donor-specific antibodies helps avoiding hyperacute rejection of the transplanted organ. In addition, donor-specific antibodies might induce acute and chronic injuries due to antibody-mediated rejection, or cardiac allograft vasculopathy^{70,71}. The downside of this selection process is that the higher the number of unacceptable antigens, the narrower the donor pool³. The definition of what is an unacceptable antigen is therefore essential but remains highly controversial (level of Mean Fluorescence Intensity, in vitro complement fraction C1q binding, dilution)⁷².

Since heart transplantation is a vital therapeutic option, some centers opt to cross HLA barriers and manage donor specific antibodies subsequently⁷³. A peri-operative combination of plasmapheresis and high-dose intravenous immunoglobulins can be used to reduce donor-specific antibodies plasma levels in patients at moderate immunological risk. For higher-risk patients, an intensification

of the immunosuppression may be required. The early inhibition of the complement cascade is an attractive approach due its major implication in antibody-related acute allograft injury.

Maintenance immunosuppressive therapy

The early maintenance immunosuppressive therapy usually relies on a triple drug regimen: calcineurin inhibitor (tacrolimus, cyclosporine), cell-cycle inhibitor (mycophenolate mofetil, mycophenolic acid) and corticosteroids¹⁶. Table 3 summarizes the doses, side effects and monitoring of each drug with a particular focus on short-term management in the ICU.

Treatment of cardiac allograft rejection

The pathologic evaluation of endomyocardial biopsies remains the gold-standard to monitor, diagnose and classify heart allograft rejection. The International Society for Heart and Lung Transplantation working formulations classifies acute cellular rejection from 0R to 3R according to the importance of lymphocytes infiltrates and signs of myocyte injury (Figure 1A) and antibody-mediated rejection from 0 to 3 according to the presence of histologic (microvascular inflammation) and immunopathologic (complement C4d deposition in capillaries, presence of intravascular macrophages) signs of antibody-mediated rejection (Figure 1B)^{74,75}.

This international classification is the guide to rejection therapies. The presence of an acute allograft dysfunction is always considered as a marker of the severity of an ongoing rejection and should prompt aggressive immunosuppressive strategies. While the treatment of acute cellular rejection is well described and consensual (corticosteroids , anti-thymocyte globulin in the case of severe graft dysfunction)¹⁶, the treatment of antibody-mediated rejection—remains controversial⁷⁶. Plasmapheresis and high-doses of intravenous immunoglobulins represent the first-line therapy but a more aggressive immunosuppressive strategy may be required, particularly in case of allograft dysfunction^{77,78} (Table 3).

Infectious complications

Infections are the leading cause of death within the first year after heart transplantation and justify targeted prophylaxis⁷⁹. The development of infection can be facilitated by the level of immunosuppression, drug-induced leukopenia or immunomodulation by viral infection such as cytomegalovirus⁸⁰. A classic timeline describes 3 distinct periods of infection after solid organ transplantation: 1) the postoperative period within the first month is characterized by nosocomial and donor-derived infections (cytomegalovirus, Epstein-Barr virus or *Toxoplasma* spp.), 2) the second period, up to 6 months after surgery, with opportunistic infections, and 3) after 6 months, community-acquired or rare infectious agents are expected. However epidemiologic data are scarce, not recent (>10 years), with various methodologies and from a limited number of centers which makes generalization difficult. The two most recent cohorts, with a follow-up comprised between 3 months and one-year, found a high incidence of infection (60 to 80%) after heart transplantation with the highest rate within the first month^{81,82}. Among infectious agents, bacteria were the most frequently involved (>50%), viruses were also frequent (30%), whereas fungal infection accounted for only 13-14%. The predominant pathogens were Enterobacteriaceae and Herpesviruses. Multidrug resistant bacteria were frequent (15-20% of the cases). Respiratory tract and bloodstream were the most frequent bacterial infection sites, whereas viral infections were mostly mucocutaneous and respiratory. Although less represented, surgical site infections may be more prevalent (9-10%) following heart transplant than other cardiac surgeries^{81,83,84}. Interestingly, cannulation site infection may be a frequent complication (37%) in patients supported by ECMO after heart transplantation⁸⁵.

Preventive strategies based on pharmacological prophylaxis according to serologic status of the donor or recipient are recommended by the International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients¹⁶, and are summarized in Table 4. Prophylaxis against *Pneumocystis jirovecii* and *Toxoplasma gondii* is recommended during the early postoperative

period, usually with Trimethoprim/Sulfamethoxazole, if not contraindicated. Anti-fungal prophylaxis to prevent mucocutaneous candidiasis or aspergillosis is not routinely recommended but may be considered in case of specific risk factors for aspergillosis. High risk patients for cytomegalovirus infection (seronegative patients with seropositive donors), should benefit from antiviral prophylaxis (ganciclovir or valganciclovir) within 10 days after the transplantation for at least 3 months⁸⁶. Seropositive patients may benefit from antiviral prophylaxis or from a preemptive strategy according to the center preference⁸⁷. In the latter, cytomegalovirus viral load is quantified by nucleic acid amplification testing at least weekly in the whole blood, and an antiviral treatment is initiated only when a predetermined threshold is achieved. However, no specific threshold can be recommended given the inter-assay and patient-related factors variabilities. A preemptive strategy might prevent late cytomegalovirus infection, drug toxicity, and reduce cost. Conversely, universal prophylaxis is easier to implement, prevents other herpes virus infections and may prevent opportunistic infections or graft rejection⁸⁶. Antimicrobial prophylaxis before the surgery with activity against skin flora, including *Staphylococcus aureus* is recommended to prevent surgical site infections¹⁶. If a chronic infection of ventricular-assist device, pacemaker or defibrillator is present, a perioperative antibiotic therapy based on known microbiologic susceptibilities should be initiated after consultation of an infectious disease specialist. Non-pharmacologic strategies range from standard precaution to protective isolation. Standard precautions are recommended for all patient care and include hand hygiene, personal protective equipment in case of possible exposure to infectious material, respiratory hygiene, adequate environment cleaning, adequate handling and disinfection of patient care equipment and instrument, and safe injection practices. Despite the lack of evidence protective isolation seems very frequent in heart transplant centers across the world with an important variability in the measures used, high-touch surface disinfection, private rooms and daily linen change being the more frequent measures used⁸⁸.

Hemostasis and transfusion management

The treatment of postoperative hemorrhage and transfusion protocols following transplantation are poorly described. Furthermore, these patients are largely under-represented and seldom studied in prospective trials investigating bleeding and transfusion in cardiac surgery⁸⁹⁻⁹³. In the absence of specific data and guidelines, perioperative hemostasis and transfusion management in heart transplantation should probably follow current guidelines for cardiac surgery, including preoperative management of antithrombotic drugs, cardiopulmonary bypass optimization, algorithm-guided therapy for perioperative bleeding, use of viscoelastic testing^{94,95}. A suggested perioperative bleeding management protocol is provided (see figure, Supplemental Digital Content 2).

Preoperative Vitamin K antagonists (VKA) should be reversed during surgery using vitamin K and INR-guided four-factor prothrombin complex concentrates^{16,96}. In the situation where a direct oral anticoagulant (DOAC) is preferred over VKA, it is appropriate to choose dabigatran rather than anti-Xa DOACs, in combination with a protocol for reversal using idarucizumab⁹⁷. While aspirin can safely be continued, uninterrupted P2Y₁₂ inhibitors might increase postoperative bleeding and should be avoided in patients awaiting heart transplantation^{16,98}. In the case of a formal indication for dual antiplatelet therapy, thienopyridines (clopidogrel, prasugrel) should be preferred due to the inefficacy of platelet transfusion in neutralizing ticagrelor when the last intake is less than 24 hours before surgery⁹⁹. Antiplatelet agents' reversal using platelet concentrates should be considered in case of severe perioperative bleeding and may be guided by platelet function testing⁹⁹.

Overall, heart transplant seems to be associated with a risk of severe perioperative bleeding and a high exposition to allogeneic transfusion, especially in the setting of redo surgery and bridge to transplantation using ECMO or ventricular assist device support¹⁰⁰⁻¹⁰³. In accordance with cardiac surgery guidelines, post-operative bleeding should be managed using a tailored goal-directed hemostatic protocol, in coordination with the hemostasis specialist (see figure, Supplemental Digital Content 2). Special attention should be paid to patient supported by ECMO or ventricular assist device, which are associated with platelet function defects and acquired von Willebrand syndrome,

although little evidence is available regarding the impact of platelet transfusion or von Willebrand factor concentrate in this setting^{104,105}.

In the absence of specific data, a restrictive erythrocyte transfusion strategy (hemoglobin threshold between 7.5 and 8 g/dL) should probably be used for heart transplantation, potentially tailored to tissue perfusion/oxygenation values, including central venous oxygen saturation^{94,106}. As for patients with chronic heart failure, including those awaiting heart transplantation, postoperative anemia and iron deficiency warrant particular attention and may justify intravenous iron therapy in case of significant bleeding and/or postoperative iron deficiency^{107,108}.

Heart transplantation patients are at increased risk of venous thromboembolism and should receive pharmacological prophylaxis, primarily using low molecular weight heparin¹⁰⁹. Antiplatelet therapy using low-dose aspirin is usually initiated early after surgery and would seem to be associated with a reduction of cardiac allograft vasculopathy¹¹⁰.

Mechanical Ventilation

In the absence of specific data in heart transplantation patients, ventilation strategies recommendations can be inferred from cardiac surgery literature. Intraoperative protective ventilation with tidal volume between 6 to 8 mL/kg of predicted body weight and PEEP at 5 cmH₂O may be recommended according to studies performed in non-cardiac major surgery¹¹¹. However, open-lung ventilation with higher PEEP and lung recruitment maneuvers or ventilation during bypass remain controversial to date¹¹²⁻¹¹⁴. Interestingly, mechanical ventilation prior to heart transplantation is strongly associated with increased mortality¹¹⁵. Early extubation within 6 hours of ICU admission should be achieved whenever possible¹¹⁶. Importantly, extubation may be also achieved safely in patients on veno arterial ECMO with clinical benefit¹¹⁷.

Acute kidney injury

Early post-operative acute kidney injury is frequent in the first seven days after heart transplantation, with an incidence between 40% to 76% according to Kidney Disease: Improving Global Outcomes classification. Renal replacement therapy is required in 7% to 19% of patients¹¹⁸⁻¹²⁰. Furthermore, recent studies demonstrate a trend toward an increased incidence of all Kidney Disease: Improving Global Outcomes stages of acute kidney injury over time^{118,119}. The preoperative factors independently associated with early acute kidney injury include higher body mass index, diabetes and chronic kidney disease^{118,119,121,122}. In addition, longer cardiopulmonary bypass time, postoperative hemodynamic instability, ECMO support, severe bleeding and early initiation of calcineurin inhibitors are independent predictors of early acute kidney injury^{118,119,121}. The pathogenesis of heart transplantation-associated acute kidney injury mainly involves type 1 and type 2 cardiorenal syndrome¹²³. Among potential mechanisms, a close attention should be paid to right heart hemodynamics, especially preoperative pulmonary hypertension, postoperative right ventricular failure and renal congestion, which appears as a strong predictor of early acute kidney injury^{120,124-126}. Severe postoperative acute kidney injury is associated with a higher incidence of chronic kidney disease, rejection and mortality at 1-year after heart transplant^{118,119,127}. Although there is no single pharmacological treatment, heart transplant patients might benefit from early prediction and recognition of postoperative acute kidney injury and multimodal bundle implementation^{120,128,129}. Specific actions might include postponing calcineurin inhibitors, providing both left and right ventricle support (inotropes, pulmonary vasodilators, circulatory support) and minimizing renal congestion.

Nutrition

Nutritional status is crucial but often underestimated in heart failure patients. Yet, cachexia and sarcopenia may occur in at least 10% to 20% of ambulatory patients with systolic heart failure¹³⁰.

Therefore, the Heart Failure Society of America proposed in a recent consensus statement a nutritional evaluation and counseling for patients with heart failure proposed for heart transplantation¹³⁰. In the postoperative period, early enteral nutrition is recommended including also patients receiving extracorporeal membrane oxygenation¹³¹. Oral intake should be the preferred route whenever possible. In patients with uncontrolled shock, enteral feeding must be delayed but low dose of enteral nutrition can be started as soon as shock is controlled. However, in case of low cardiac output requiring inotropic support, the risk of acute mesenteric ischemia requires cautious enteral nutrition introduction, or even delayed introduction¹³². In addition, heart transplantation is frequently associated with hyperglycemia in both diabetic and non-diabetic patients, requiring continuous insulin infusion in ICU to maintain glycemic control^{16,133}.

Conclusion

Early postoperative mortality following heart transplantation remains high despite substantial improvements over recent years. Therefore, optimal perioperative management of these patients is crucial. Unfortunately, most of the evidence supporting the current recommendations is mainly based on retrospective studies with limited sample size or is adapted from general cardiac surgery practices. Therefore, collaborative research networks at the international level should be strongly encouraged to improve the knowledge and, hopefully, the outcome of heart transplant patients.

Acknowledgments

The authors express their gratitude to Mary Regan, M.D., for proofreading.

References

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, Group ESD: Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2021; 42:ehab670
2. Khush KK, Hsich E, Potena L, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Perch M, Sadavarte A, Toll A, Singh TP, Zuckermann A, Stehlik J, Transplantation for the IS for H and L: The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient characteristics. *J Heart Lung Transplant* 2021; 40:1035–49
3. Kransdorf EP, Kittleson MM, Patel JK, Pando MJ, Steidley DE, Kobashigawa JA: Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. *J Heart Lung Transplant* 2017; 36:787–96
4. Kobashigawa J, Colvin M, Potena L, Dragun D, Crespo-Leiro MG, Delgado JF, Olymbios M, Parameshwar J, Patel J, Reed E, Reinsmoen N, Rodriguez ER, Ross H, Starling RC, Tyan D, Urschel S, Zuckermann A: The management of antibodies in heart transplantation: An ISHLT consensus document. *J Heart Lung Transplant* 2018; 37:537–47
5. Crespo-Leiro MG, Costanzo MR, Gustafsson F, Khush KK, Macdonald PS, Potena L, Stehlik J, Zuckermann A, Mehra MR: Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies. *Eur Heart J* 2022; 43:e hac204-
6. Shelton KT, Wiener-Kronish JP: Evolving Role of Anesthesiology Intensivists in Cardiothoracic Critical Care. *Anesthesiology* 2020; 133:1120–6
7. Chan JL, Kobashigawa JA, Aintablian TL, Li Y, Perry PA, Patel JK, Kittleson MM, Czer LS, Zarrini P, Velleca A, Rush J, Arabia FA, Trento A, Esmailian F: Vasoplegia after heart transplantation: outcomes at 1 year†. *Interact Cardiovasc Th* 2017; 25:212–7
8. Batchelor RJ, Wong N, Liu DH, Chua C, William J, Tee SI, Sata Y, Bergin P, Hare J, Leet A, Taylor AJ, Patel HC, Burrell A, McGiffin D, Kaye DM: Vasoplegia Following Orthotopic Heart Transplantation: Prevalence, Predictors and Clinical Outcomes. *J Card Fail* 2022; 28:617–26
9. Busse LW, Barker N, Petersen C: Vasoplegic syndrome following cardiothoracic surgery—review of pathophysiology and update of treatment options. *Crit Care* 2020; 24:36
10. Ltaief Z, Ben-Hamouda N, Rancati V, Gunga Z, Marcucci C, Kirsch M, Liaudet L: Vasoplegic Syndrome after Cardiopulmonary Bypass in Cardiovascular Surgery: Pathophysiology and Management in Critical Care. *J Clin Medicine* 2022; 11:6407

11. Chan JL, Kobashigawa JA, Aintablian TL, Dimbil SJ, Perry PA, Patel JK, Kittleson MM, Czer LS, Zarrini P, Velleca A, Rush J, Arabia FA, Trento A, Esmailian F: Characterizing Predictors and Severity of Vasoplegia Syndrome After Heart Transplantation. *Ann Thorac Surg* 2018; 105:770–7
12. Patarroyo M, Simbaqueba C, Shrestha K, Starling RC, Smedira N, Tang WHW, Taylor DO: Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. *J Heart Lung Transplant* 2012; 31:282–7
13. Levin MA, Lin H-M, Castillo JG, Adams DH, Reich DL, Fischer GW: Early On–Cardiopulmonary Bypass Hypotension and Other Factors Associated With Vasoplegic Syndrome. *Circulation* 2009; 120:1664–71
14. Asleh R, Alnsasra H, Schettle SD, Taher R, Dunlay S, Stulak J, Daly R, Behfar A, Pereira N, Clavell A, Maltais S, Frantz R, Edwards B, Kushwaha S: Predictors and clinical outcomes of vasoplegia in patients bridged to heart transplantation with continuous flow left ventricular assist devices. *J Am Coll Cardiol* 2019; 73:977
15. Weis F, Kilger E, Beiras-Fernandez A, Nassau K, Reuter D, Goetz A, Lamm P, Reindl L, Briegel J: Association between vasopressor dependence and early outcome in patients after cardiac surgery. *Anaesthesia* 2006; 61:938–42
16. Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, Farrero M, García-Guereta L, Jamero G, Khush K, Lavee J, Pouch S, Patel J, Michaud C, Shullo M, Schubert S, Angelini A, Carlos L, Mirabet S, Patel J, Pham M, Urschel S, Kim K-H, Miyamoto S, Chih S, Daly K, Grossi P, Jennings D, Kim I, Lim HS, Miller T, Potena L, Velleca A, Eisen H, Bellumkonda L, Danziger-Isakov L, Dobbels F, Harkess M, Kim D, Lyster H, Peled Y, Reinhardt Z: The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. *J Heart Lung Transplant* 2022 doi:10.1016/j.healun.2022.09.023
17. Hajjar LA, Vincent JL, Galas FRBG, Rhodes A, Landoni G, Osawa EA, Melo RR, Sundin MR, Grande SM, Gaiotto FA, Pomerantzeff PM, Dallan LO, Franco RA, Nakamura RE, Lisboa LA, Almeida JP de, Gerent AM, Souza DH, Gaiane MA, Fukushima JT, Park CL, Zambolim C, Ferreira GSR, Strabelli TM, Fernandes FL, Camara L, Zeferino S, Santos VG, Piccioni MA, Jatene FB, Auler JOC, Filho RK: Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery. *Anesthesiology* 2017; 126:85–93
18. Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR, Edwards NM, Landry DW, Oz MC: Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. *J Heart Lung Transplant* 1999; 18:814–7
19. Kofidis T, Strüber M, Wilhelmi M, Anssar M, Simon A, Harringer W, Haverich A: Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. *J Thorac Cardiovasc Surg* 2001; 122:823–4
20. Klijian A, Khanna AK, Reddy VS, Friedman B, Ortoleva J, Evans AS, Panwar R, Kroll S, Greenfield CR, Chatterjee S: Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study. *J Cardiothor Vasc An* 2021; 35:51–8

21. Levin RL, Degrange MA, Bruno GF, Mazo CDD, Taborda DJ, Griotti JJ, Boullon FJ: Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. *Ann Thorac Surg* 2004; 77:496–9
22. Shah PR, Reynolds PS, Pal N, Tang D, McCarthy H, Spiess BD: Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: a case series. *Can J Anesthesia J Can D'anesthésie* 2018; 65:560–8
23. Wieruszewski PM, Radosevich MA, Kashani KB, Daly RC, Wittwer ED: Synthetic Human Angiotensin II for Postcardiopulmonary Bypass Vasoplegic Shock. *J Cardiothor Vasc An* 2019; 33:3080–4
24. Kobashigawa J, Zuckermann A, Macdonald P, Leprince P, Esmailian F, Luu M, Mancini D, Patel J, Razi R, Reichensperner H, Russell S, Segovia J, Smedira N, Stehlik J, Wagner F, participants on behalf of the CC: Report from a consensus conference on primary graft dysfunction after cardiac transplantation. *J Heart Lung Transplant* 2014; 33:327–40
25. Truby LK, DeRoo S, Spellman J, Jennings DL, Takeda K, Fine B, Restaino S, Farr M: Management of primary graft failure after heart transplantation: Preoperative risks, perioperative events, and postoperative decisions. *Clin Transplant* 2019; 33:e13557
26. Segovia J, Cosío MDG, Barceló JM, Bueno MG, Pavía PG, Burgos R, Serrano-Fiz S, García-Montero C, Castedo E, Ugarte J, Alonso-Pulpón L: RADIAL: A novel primary graft failure risk score in heart transplantation. *J Heart Lung Transplant* 2011; 30:644–51
27. Carmena MDGC, Bueno MG, Almenar L, Delgado JF, Arizón JM, Vilchez FG, Crespo-Leiro MG, Mirabet S, Roig E, Villa FP, Fernández-Yañez JF, Lambert JL, Manito N, Fuente L, Julve MLS, Pascual D, Rábago G, Millán I, Alonso-Pulpón LA, Segovia J: Primary graft failure after heart transplantation: Characteristics in a contemporary cohort and performance of the RADIAL risk score. *J Heart Lung Transplant* 2013; 32:1187–95
28. Truby LK, Takeda K, Topkara VK, Takayama H, Garan AR, Yuzefpolskaya M, Colombo P, Naka Y, Farr M: Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 2018; 37:1433–42
29. R-Shalom Y, Segall A, Budenaers D: Decision and estimation procedures for air contaminants. *Am Ind Hyg Assoc J* 1976; 37:469–73
30. Urbanowicz T, Ligowski M, Camacho E, Walczak M, Straburzyńska-Migaj E, Tomczyk J, Jemielity M: Effect of Milrinone Therapy on Splanchnic Perfusion after Heart Transplantation. *Ann Transpl* 2014; 19:472–7
31. Weis F, Beiras-Fernandez A, Kaczmarek I, Sodian R, Kur F, Weis M, Schmoeckel M, Reichart B: Levosimendan: A New Therapeutic Option in the Treatment of Primary Graft Dysfunction After Heart Transplantation. *J Heart Lung Transplant* 2009; 28:501–4
32. Takeda K, Li B, Garan AR, Topkara VK, Han J, Colombo PC, Farr MA, Naka Y, Takayama H: Improved outcomes from extracorporeal membrane oxygenation versus ventricular assist device temporary support of primary graft dysfunction in heart transplant. *J Heart Lung Transplant* 2017; 36:650–6

33. Lepère V, Duceau B, Lebreton G, Bombled C, Dujardin O, Boccara L, Charfeddine A, Amour J, Hajage D, Bouglé A: Risk Factors for Developing Severe Acute Kidney Injury in Adult Patients With Refractory Postcardiotomy Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation. *Crit Care Med* 2020; 48:e715–21
34. Noly P-E, Hébert M, Lamarche Y, Cortes JR, Mauduit M, Verhoye J-P, Voisine P, Flécher E, Carrier M: Use of extracorporeal membrane oxygenation for heart graft dysfunction in adults: incidence, risk factors and outcomes in a multicentric study. *Can J Surg* 2021; 64:E567–77
35. M'Pembele R, Roth S, Stroda A, Buse GL, Sixt SU, Westenfeld R, Polzin A, Rellecke P, Tudorache I, Hollmann MW, Aubin H, Akhyari P, Lichtenberg A, Huhn R, Boeken U: Life impact of VA-ECMO due to primary graft dysfunction in patients after orthotopic heart transplantation. *Esc Heart Fail* 2022; 9:695–703
36. Grandin EW, Nunez JI, Willar B, Kennedy K, Rycus P, Tonna JE, Kapur NK, Shaefi S, Garan AR: Mechanical Left Ventricular Unloading in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation. *J Am Coll Cardiol* 2022; 79:1239–50
37. Klima U, Ringes-Lichtenberg S, Warnecke G, Lichtenberg A, Strüber M, Haverich A: Severe right heart failure after heart transplantation. A single-center experience. *Transplant Int* 2005; 18:326–32
38. Ortiz V, Martínez-Dolz L, Ten F, Almenar L, Sánchez-Lacuesta E, Moro J, Sánchez-Lázaro I, Sánchez-Soriano R, Cano O, Salvador A: Evolution of Right Cardiac Pressures During the First Year After Heart Transplantation. *Transplant P* 2007; 39:2368–71
39. Molquentin J-P, Nägele MP, Frank M, Sudano I, Enseleit F, Wilhelm MJ, Lüscher TF, Maisano F, Ruschitzka F, Flammer AJ: Prognostic value of mean pulmonary artery pressure in the stable phase after heart transplantation. *Eur J Cardio-thorac* 2017; 52:775–80
40. Harjola V, Mebazaa A, Čelutkienė J, Bettex D, Bueno H, Chioncel O, Crespo-Leiro MG, Falk V, Filippatos G, Gibbs S, Leite-Moreira A, Lassus J, Masip J, Mueller C, Mullens W, Naeije R, Nordegraaf AV, Parissis J, Riley JP, Ristic A, Rosano G, Rudiger A, Ruschitzka F, Seferovic P, Sztrymf B, Vieillard-Baron A, Yilmaz MB, Konstantinides S: Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. *Eur J Heart Fail* 2016; 18:226–41
41. Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, Marelli D, Beygui R, Shemin R, Watson L, Vartapetian I, Ardehali A: A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. *J Thorac Cardiovasc Surg* 2009; 138:1417–24
42. Krebs R, Morita Y: Inhaled Pulmonary Vasodilators and Thoracic Organ Transplantation: Does Evidence Support Its Use and Cost Benefit? *Seminars Cardiothorac Vasc Anesthesia* 2020; 24:67–73
43. Elmi-Sarabi M, Jarry S, Couture EJ, Haddad F, Cogan J, Sweatt AJ, Rousseau-Saine N, Beaubien-Souligny W, Fortier A, Denault AY: Pulmonary Vasodilator Response of Combined Inhaled Epoprostenol and Inhaled Milrinone in Cardiac Surgical Patients. *Anesthesia Analgesia* 2023; 136:282–94

44. Carrozzini M, Merlanti B, Olivieri GM, Lanfranconi M, Bruschi G, Mondino M, Russo CF: Percutaneous RVAD with the Protek Duo for severe right ventricular primary graft dysfunction after heart transplant. *J Heart Lung Transplant* 2021; 40:580–3
45. Nicoara A, Ruffin D, Cooter M, Patel CB, Thompson A, Schroder JN, Daneshmand MA, Hernandez AF, Rogers JG, Podgoreanu MV, Swaminathan M, Kretzer A, Stafford-Smith M, Milano CA, Bartz RR: Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors. *Am J Transplant* 2018; 18:1461–70
46. Vaseghi M, Boyle NG, Kedia R, Patel JK, Cesario DA, Wiener I, Kobashigawa JA, Shivkumar K: Supraventricular Tachycardia After Orthotopic Cardiac Transplantation. *J Am Coll Cardiol* 2008; 51:2241–9
47. Ahmari SAL, Bunch TJ, Chandra A, Chandra V, Ujino K, Daly RC, Kushwaha SS, Edwards BS, Maalouf YF, Seward JB, McGregor CG, Chandrasekaran K: Prevalence, Pathophysiology, and Clinical Significance of Post-heart Transplant Atrial Fibrillation and Atrial Flutter. *J Heart Lung Transplant* 2006; 25:53–60
48. Mariscalco G, Engström KG: Postoperative Atrial Fibrillation Is Associated With Late Mortality After Coronary Surgery, but Not After Valvular Surgery. *Ann Thorac Surg* 2009; 88:1871–6
49. Vakil K, Taimeh Z, Sharma A, Abidi KS, Colvin M, Luepker R, Levy WC, Adabag S: Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. *Heart Rhythm* 2014; 11:1684–90
50. Alba AC, Foroutan F, Hing NKVNF, Fan CS, Manlhiot C, Ross HJ: Incidence and predictors of sudden cardiac death after heart transplantation: A systematic review and meta-analysis. *Clin Transplant* 2018; 32:e13206
51. Alba AC, Fan CS, Manlhiot C, Dipchand AI, Stehlik J, Ross HJ: The evolving risk of sudden cardiac death after heart transplant. An analysis of the ISHLT Thoracic Transplant Registry. *Clin Transplant* 2019; 33:e13490
52. Joglar JA, Wan EY, Chung MK, Gutierrez A, Slaughter MS, Bateson BP, Loguidice M, Drazner M, Kistler PM, Saour B, Poole JE, Murtaza G, Turagam MK, Vader J, Lakkireddy D, Birati EY, Dhingra R, Gopinathannair R: Management of Arrhythmias After Heart Transplant. *Circulation Arrhythmia Electrophysiol* 2021; 14:e007954
53. Benck L, Kransdorf EP, Emerson DA, Rushakoff J, Kittleson MM, Klapper EB, Megna DJ, Esmailian F, Halprin C, Trento A, Ramzy D, Czer LSC, Chang DH, Ebinger JE, Kobashigawa JA, Patel JK: Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant. *J Heart Lung Transplant* 2021; 40:970–80
54. Buchan TA, Moayedi Y, Truby LK, Guyatt G, Posada JD, Ross HJ, Khush KK, Alba AC, Foroutan F: Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis. *J Heart Lung Transplant* 2021; 40:642–51
55. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland Jr JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. *Circulation* 2019; 140:e125–51

56. Noworolski R, Przybylowski P, Majewski J, Sadowski J, Lelakowski J: Early and Late Indications for Implantation of Cardiac Pacemakers in Patients After Heart Transplantation: A Single-Center Experience. *Transplant P* 2011; 43:3074–5
57. Herrmann FEM, Wellmann P, Sadoni S, Schramm R, Hagl C, Juchem G: Sinus node dysfunction after heart transplantation—An analysis of risk factors and atrial pacing burden. *Clin Transplant* 2018; 32:e13202
58. Doulamis IP, Wu B, Akbar AF, Xanthopoulos A, Androulakis E, Briasoulis A: Pacemaker Implantation following Heart Transplantation: Analysis of a Nation-Wide Database. *J Clin Medicine* 2023; 12:1604
59. Cui G, Kobashigawa J, Margarian A, Sen L: Cause of atrioventricular block in patients after heart transplantation. *Transplantation* 2003; 76:137–42
60. Roest S, Manintveld OC, Kolff MAE, Akca F, Veenis JF, Constantinescu AA, Brugts JJ, Birim O, Osch-Gevers LM, Szili-Torok T, Caliskan K: Cardiac allograft vasculopathy and donor age affecting permanent pacemaker implantation after heart transplantation. *Esc Heart Fail* 2022; 9:1239–47
61. Wong RC-C, Abrahams Z, Hanna M, Pangrace J, Gonzalez-Stawinski G, Starling R, Taylor D: Tricuspid Regurgitation After Cardiac Transplantation: An Old Problem Revisited. *J Heart Lung Transplant* 2008; 27:247–52
62. Kim HR, Kim HJ, Lee SE, Jung S-H, Yun T-J, Kim JJ, Lee JW: Prevalence and Risk Factors of Post-heart Transplant Tricuspid Regurgitation. *Transplantation* 2022; 106:e297–303
63. López-Vilella R, Paniagua-Martín MJ, González-Vílchez F, Trenado VD, Barge-Caballero E, Sánchez-Lázaro I, Fernández AVA, Martínez-Dolz L, Crespo-Leiro MG, Almenar-Bonet L: Epidemiological Study of Tricuspid Regurgitation After Cardiac Transplantation. Does it Influence Survival? *Transplant Int* 2022; 35:10197
64. Aziz TM, Saad RA, Burgess MI, Campbell CS, Yonan NA: Clinical significance of tricuspid valve dysfunction after orthotopic heart transplantation. *J Heart Lung Transplant* 2002; 21:1101–8
65. Aziz TM, Burgess MI, Rahman AN, Campbell CS, Deiraniya AK, Yonan NA: Risk factors for tricuspid valve regurgitation after orthotopic heart transplantation. *Ann Thorac Surg* 1999; 68:1247–51
66. Aziz T, Burgess M, Khafagy R, Hann AW, Campbell C, Rahman A, Deiraniya A, Yonan N: Bicaval and standard techniques in orthotopic heart transplantation: Medium-term experience in cardiac performance and survival. *J Thorac Cardiovasc Surg* 1999; 118:115–22
67. Filsoofi F, Salzberg SP, Anderson CA, Couper GS, Cohn LH, Adams DH: Optimal Surgical Management of Severe Tricuspid Regurgitation in Cardiac Transplant Patients. *J Heart Lung Transplant* 2006; 25:289–93
68. Khush KK, Potena L, Cherikh WS, Chambers DC, Harhay MO, Hayes D, Hsich E, Sadavarte A, Singh TP, Zuckermann A, Stehlik J, Transplantation F the IS for H and L: The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report—2020; focus on deceased donor characteristics. *J Heart Lung Transplant* 2020; 39:1003–15

69. Aliabadi A, Grömmner M, Cochrane A, Salameh O, Zuckermann A: Induction therapy in heart transplantation: where are we now? *Transplant Int* 2013; 26:684–95
70. Clerkin KJ, Farr MA, Restaino SW, Zorn E, Latif F, Vasilescu ER, Marboe CC, Colombo PC, Mancini DM: Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. *J Heart Lung Transplant* 2017; 36:540–5
71. Coutance G, Orio V d', Belin L, Bréchet N, Saheb S, Lebreton G, Bouglé A, Rouvier P, Gautreau C, Ouldammam S, Chamillard X, Huot M, Amour J, Combes A, Leprince P, Varnous S: Favorable outcome of an exclusively posttransplant prophylactic strategy after heart transplantation in recipients with high immunological risk. *Transplantation* 2018; Publish Ahead of Print:NA;
72. Tambur AR, Campbell P, Chong AS, Feng S, Ford ML, Gebel H, Gill RG, Kelsoe G, Kosmoliaptsis V, Mannon RB, Mengel M, Reed EF, Valenzuela NM, Wiebe C, Dijke IE, Sullivan HC, Nickerson P: Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. *Am J Transplant* 2020; 20:2652–68
73. Kobashigawa J, Mehra M, West L, Kerman R, George J, Rose M, Zeevi A, Reinsmoen N, Patel J, Reed EF, Participants CC: Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation. *J Heart Lung Transplant* 2009; 28:213–25
74. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciú-Focia N, Zeevi A, Billingham ME: Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection. *J Heart Lung Transplant* 2005; 24:1710–20
75. Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, Goddard M, Hammond EH, Leone O, Marboe C, Miller D, Neil D, Rassl D, Revelo MP, Rice A, Rodriguez ER, Stewart S, Tan CD, Winters GL, West L, Mehra MR, Angelini A: The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant* 2013; 32:1147–62
76. Colvin MM, Cook JL, Chang P, Francis G, Hsu DT, Kiernan MS, Kobashigawa JA, Lindenfeld J, Masri SC, Miller D, O'Connell J, Rodriguez ER, Rosengard B, Self S, White-Williams C, Zeevi A, Cardiology AHAHF and TC of the C on C, Resuscitation AHAHF and TC of the C on CCC Perioperative and, Young AHAHF and TC of the C on CD in the, Nursing AHAHF and TC of the C on CC Council on Cardiovascular and Stroke, Intervention AHAHF and TC of the C on CR and, Anesthesia AHAHF and TC of the C on CS and: Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. *Circulation* 2015; 131:1608–39
77. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciú-Foca N, Tallaj J, Taylor DO, Bakel AV, West L, Zeevi A, Zuckermann A, Participants CC: Report from a consensus conference on antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant* 2011; 30:252–69

78. Coutance G, Aelst LV, Hékimian G, Vidal C, Rouvier P, Saheb S, Gautreau C, Leprince P, Varnous S: Antibody-mediated rejection induced cardiogenic shock: Too late for conventional therapy. *Clin Transplant* 2018; 32:e13253
79. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, Meiser B, Rossano JW, Chambers DC, Yusef RD, Stehlik J, Transplantation for the IS for H and L: The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report—2017; Focus Theme: Allograft ischemic time. *J Heart Lung Transplant* 2017; 36:1037–46
80. Fishman JA: Infection in Solid-Organ Transplant Recipients. *New Engl J Medicine* 2007; 357:2601–14
81. Pons S, Sonnevile R, Bouadma L, Styfalova L, Ruckly S, Neuville M, Radjou A, Lebut J, Dilly M-P, Mourvillier B, Dorent R, Nataf P, Wolff M, Timsit J-F: Infectious complications following heart transplantation in the era of high-priority allocation and extracorporeal membrane oxygenation. *Ann Intensive Care* 2019; 9:17
82. Delden C van, Stampf S, Hirsch HH, Manuel O, Meylan P, Cusini A, Hirzel C, Khanna N, Weisser M, Garzoni C, Boggian K, Berger C, Nadal D, Koller M, Saccilotto R, Mueller NJ, Study STC, Amico P, Aubert J-D, Banz V, Beldi G, Benden C, Berger C, Binet I, Bochud P-Y, Branca S, Bucher H, Carell T, Catana E, Chalandon Y, Geest S de, Rougemont O de, Dickenmann M, Duchosal M, Elkrief L, Fehr T, Ferrari-Lacraz S, Garzoni C, Soccia PG, Gaudet C, Giostra E, Golshayan D, Hadaya K, Halter J, Hauri D, Heim D, Hess C, Hillinger S, Hirsch HH, Hofbauer G, Huynh-Do U, Immer F, Klaghofer R, Koller M, Laesser B, Laube G, Lehmann R, Lovis C, Majno P, Manuel O, Marti H-P, Martin PY, Martinelli M, Meylan P, Mueller NJ, Müller A, Müller T, Müllhaupt B, Pascual M, Passweg J, Posfay-Barbe K, Rick J, Roosnek E, Rosselet A, Rothlin S, Ruschitzka F, Schanz U, Schaub S, Schnyder A, Seiler C, Sprachta J, Stampf S, Steiger J, Stirnimann G, Toso C, Delden CV, Venetz J-P, Villard J, Wick M, Wilhelm M, Yerly P: Burden and Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss Transplant Cohort Study. *Clin Infect Dis* 2020; 71:e159–69
83. Schreiber PW, Lang BM, Boggian K, Neofytos D, Delden C van, Egli A, Dickenmann M, Hillinger S, Hirzel C, Manuel O, Desgranges F, Koller M, Rossi S, Stampf S, Wilhelm MJ, Kuster SP, Mueller NJ, (STCS) STCS: Incidence and outcome of surgical site infections in thoracic-organ transplant recipients registered in the Swiss Transplant Cohort Study. *J Heart Lung Transplant* 2022 doi:10.1016/j.healun.2022.04.011
84. Massart N, Mansour A, Ross JT, Piau C, Verhoye J-P, Tattevin P, Nessler N: Mortality due to hospital-acquired infection after cardiac surgery. *J Thorac Cardiovasc Surg* 2022; 163:2131-2140.e3
85. Coutance G, Jacob N, Demondion P, Nguyen LS, Bouglé A, Bréchet N, Varnous S, Leprince P, Combes A, Lebreton G: Favorable Outcomes of a Direct Heart Transplantation Strategy in Selected Patients on Extracorporeal Membrane Oxygenation Support. *Crit Care Med* 2020; 48:498–506
86. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A, Group TTSICC: The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation* 2018; 102:900–31
87. Boutolleau D, Coutance G, Désiré E, Bouglé A, Bréchet N, Leprince P, Varnous S: Association between cytomegalovirus infection and allograft rejection in a large contemporary cohort of heart transplant recipients. *Transpl Infect Dis* 2021; 23:e13569

88. Alaerts E, Dreesen C, Denhaerynck K, Gryp S, Cleemput JV, Schuermans A, Russell CL, Dobbels F, Geest SD, team for the B study: Variability in practice patterns regarding protective isolation measures after heart transplantation: A secondary analysis of the international BRIGHT study. *Am J Infect Control* 2020; 48:786–90
89. Karkouti K, Callum J, Wijeyesundera DN, Rao V, Crowther M, Grocott HP, Pinto R, Scales DC, Investigators T, Achen B, Brar S, Morrison D, Wong D, Bussi eres JS, Waal T de, Harle C, M edicis E de, McAdams †C., Syed S, Tran D, Waters T: Point-of-Care Hemostatic Testing in Cardiac Surgery. *Circulation* 2016; 134:1152–62
90. Callum J, Farkouh ME, Scales DC, Heddle NM, Crowther M, Rao V, Hucke H-P, Carroll J, Grewal D, Brar S, Bussi eres J, Grocott H, Harle C, Pavenski K, Rochon A, Saha T, Shepherd L, Syed S, Tran D, Wong D, Zeller M, Karkouti K, Group FR: Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery. *Jama* 2019; 322:1966–76
91. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussi eres JS, McGuinness S, Byrne K, Chan MTV, Landoni G, Wallace S, Network AI of the ACT: Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. *New Engl J Medicine* 2017; 376:136–48
92. Shi J, Zhou C, Pan W, Sun H, Liu S, Feng W, Wang W, Cheng Z, Wang Y, Zheng Z, Group OS, Wang L, Song Y, Yu C, Wang X, Wang X, Fan H, Yang Y, Xu F, Gao G, Zhang Y, Li H, Li W, Li J, Yan F, Yuan S, Zhao Y, Zhang Y, Ji B, Zhang H, Liu J, Ma Y, Du J, Chen Z, Shi L, Fan Y, Lin H, Wang T, Lu T, Dai Z, Xie C: Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery. *Jama* 2022; 328:336–47
93. Mazer CD, Whitlock RP, Fergusson DA, Hall J, Belley-Cote E, Connolly K, Khanykin B, Gregory AJ, M edicis   de, McGuinness S, Royse A, Carrier FM, Young PJ, Villar JC, Grocott HP, Seeberger MD, Fremes S, Lellouche F, Syed S, Byrne K, Bagshaw SM, Hwang NC, Mehta C, Painter TW, Royse C, Verma S, Hare GMT, Cohen A, Thorpe KE, J uni P, Shehata N, Group TI and PACT: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery. *New Engl J Medicine* 2017; 377:2133–44
94. Pagano D, Milojevic M, Meesters MI, Benedetto U, Bolliger D, Heymann C von, Jeppsson A, Koster A, Osnabrugge RL, Ranucci M, Ravn HB, Vonk ABA, Wahba A, Boer C: 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. *Eur J Cardio-thorac* 2017; 53:79–111
95. Raphael J, Mazer CD, Subramani S, Schroeder A, Abdalla M, Ferreira R, Roman PE, Patel N, Welsby I, Greilich PE, Harvey R, Ranucci M, Heller LB, Boer C, Wilkey A, Hill SE, Nuttall GA, Palvadi RR, Patel PA, Wilkey B, Gaitan B, Hill SS, Kwak J, Klick J, Bollen BA, Shore-Lesserson L, Abernathy J, Schwann N, Lau WT: Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. *Anesthesia Analgesia* 2019; 129:1209–21
96. Erdoes G, Koster A, Ortmann E, Meesters MI, Bolliger D, Baryshnikova E, Arroyabe BMLD, Ahmed A, Lance MD, Ranucci M, Heymann C von, Agarwal S, Ravn HB: A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. *Anaesthesia* 2021; 76:381–92

97. Keer JMV, Vanassche T, Droogne W, Rex S, Rega F, Cleemput JV, Verhamme P: Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation. *Eur J Heart Fail* 2019; 21:129–31
98. Moster M, Bolliger D: Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update. *Curr Anesthesiol Reports* 2022; 12:286–96
99. Godier A, Garrigue D, Lasne D, Fontana P, Bonhomme F, Collet J, Maistre E de, Ickx B, Gruel Y, Mazighi M, Nguyen P, Vincentelli A, Albaladejo P, Lecompte T: Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR). *Anaesth Crit Care Pa* 2018; 38:289–302
100. Immohr MB, Aubin H, Erbel-Khurtsidze S, Dalyanoglu H, Bruno RR, Westenfeld R, Tudorache I, Akhyari P, Boeken U, Lichtenberg A: Impact of pretransplant left ventricular assist device support duration on outcome after heart transplantation. *Interact Cardio Th* 2021; 34:462–9
101. Hollis AL, Lowery AV, Pajoumand M, Pham SM, Slejko JF, Tanaka KA, Mazzeffi M: Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation. *Ann Cardiac Anaesth* 2016; 19:418–24
102. Nam K, Jang EJ, Kim GH, Yhim HB, Lee H, Kim DH, Ryu HG: Perioperative red blood cell transfusion and mortality following heart transplantation: A retrospective nationwide population-based study between 2007 and 2016 in Korea. *J Cardiac Surg* 2019; 34:927–32
103. Subramaniam K, Kumar A, Hernandez S, Nouraie SM: Effect of Blood Product Transfusion on Perioperative Outcomes After Heart Transplantation. *J Cardiothor Vasc An* 2021; 35:1067–72
104. Uriel N, Pak S-W, Jorde UP, Jude B, Susen S, Vincentelli A, Ennezat P-V, Cappelman S, Naka Y, Mancini D: Acquired von Willebrand Syndrome After Continuous-Flow Mechanical Device Support Contributes to a High Prevalence of Bleeding During Long-Term Support and at the Time of Transplantation. *J Am Coll Cardiol* 2010; 56:1207–13
105. Mazzeffi M, Bathula A, Tabatabai A, Menaker J, Kaczorowski D, Madathil R, Galvagno S, Pasrija C, Rector R, Tanaka K, Herr D: Von Willebrand Factor Concentrate Administration for Acquired Von Willebrand Syndrome- Related Bleeding During Adult Extracorporeal Membrane Oxygenation. *J Cardiothor Vasc An* 2021; 35:882–7
106. Zeroual N, Blin C, Saour M, David H, Aouinti S, Picot M-C, Colson PH, Gaudard P: Restrictive Transfusion Strategy after Cardiac Surgery. *Anesthesiology* 2021; 134:370–80
107. Muñoz M, Acheson AG, Bisbe E, Butcher A, Gómez-Ramírez S, Khalafallah AA, Kehlet H, Kietabl S, Liembruno GM, Meybohm P, Baikady RR, Shander A, So-Osman C, Spahn DR, Klein AA: An international consensus statement on the management of postoperative anaemia after major surgical procedures. *Anaesthesia* 2018; 73:1418–31
108. Sawicki KT, Ardehali H: Intravenous Iron Therapy in Heart Failure With Reduced Ejection Fraction: Tackling the Deficiency. *Circulation* 2021; 144:253–5

109. Kainuma A, Ning Y, Kurlansky PA, Melehy AN, Latif F, Farr MA, Sayer GT, Uriel N, Takayama H, Naka Y, Takeda K: Incidence of Deep Venous Thrombosis and its Impact on Outcomes after Heart Transplantation. *J Heart Lung Transplant* 2021; 40:S212
110. Kim M, Bergmark BA, Zelniker TA, Mehra MR, Stewart GC, Page DS, Woodcome EL, Smallwood JA, Gabardi S, Givertz MM: Early aspirin use and the development of cardiac allograft vasculopathy. *J Heart Lung Transplant* 2017; 36:1344–9
111. Young CC, Harris EM, Vacchiano C, Bodnar S, Bukowy B, Elliott RRD, Migliarese J, Ragains C, Trethewey B, Woodward A, Abreu MG de, Girard M, Futier E, Mulier JP, Pelosi P, Sprung J: Lung-protective ventilation for the surgical patient: international expert panel-based consensus recommendations. *Brit J Anaesth* 2019; 123:898–913
112. Gaudriot B, Uhel F, Gregoire M, Gacouin A, Biedermann S, Roisne A, Flecher E, Tulzo YL, Tarte K, Tadié J-M: Immune Dysfunction After Cardiac Surgery with Cardiopulmonary Bypass. *Shock* 2015; 44:228–33
113. Nguyen LS, Estagnasie P, Merzoug M, Brusset A, Koune J-DL, Aubert S, Waldmann T, Naudin C, Grinda J-M, Gibert H, Squara P: Low Tidal Volume Mechanical Ventilation Against No Ventilation During Cardiopulmonary Bypass in Heart Surgery (MECANO) A Randomized Controlled Trial. *Chest* 2021; 159:1843–53
114. Lagier D, Fischer F, Fornier W, Huynh TM, Cholley B, Guinard B, Heger B, Quintana G, Villacorta J, Gaillat F, Gomert R, Degirmenci S, Colson P, Lalande M, Benkouiten S, Minh TH, Pozzi M, Collart F, Latremouille C, Melo MFV, Velly LJ, Jaber S, Fellahi J-L, Baumstarck K, Guidon C, Group PS: Effect of open-lung vs conventional perioperative ventilation strategies on postoperative pulmonary complications after on-pump cardiac surgery: the PROVECS randomized clinical trial. *Intensive Care Med* 2019; 45:1401–12
115. Miller PE, Mullan CW, Chouairi F, Sen S, Clark KA, Reinhardt S, Fuery M, Anwer M, Geirsson A, Formica R, Rogers JG, Desai NR, Ahmad T: Mechanical ventilation at the time of heart transplantation and associations with clinical outcomes. *European Heart J Acute Cardiovasc Care* 2021; 10:843–51
116. Engelman DT, Ali WB, Williams JB, Perrault LP, Reddy VS, Arora RC, Roselli EE, Khoyneshad A, Gerdisch M, Levy JH, Lobdell K, Fletcher N, Kirsch M, Nelson G, Engelman RM, Gregory AJ, Boyle EM: Guidelines for Perioperative Care in Cardiac Surgery. *Jama Surg* 2019; 154:755–66
117. Massart N, Mansour A, Flecher E, Ross JT, Ecoffey C, Verhoye J-P, Launey Y, Auffret V, Nessler N: Clinical Benefit of Extubation in Patients on Venoarterial Extracorporeal Membrane Oxygenation. *Crit Care Med* 2021; 50:760–9
118. Thongprayoon C, Lertjitbanjong P, Hansrivijit P, Crisafio A, Mao MA, Watthanasuntorn K, Aeddula NR, Bathini T, Kaewput W, Cheungpasitporn W: Acute Kidney Injury in Patients Undergoing Cardiac Transplantation: A Meta-Analysis. *Medicines* 2019; 6:108
119. Shoji S, Kuno T, Kohsaka S, Amiya E, Asleh R, Alvarez P, Kampaktsis P, Staffa SJ, Zurakowski D, Doulamis I, Briasoulis A: Incidence and long-term outcome of heart transplantation patients who develop postoperative renal failure requiring dialysis. *J Heart Lung Transplant* 2022; 41:356–64

120. Guven G, Brankovic M, Constantinescu AA, Brugts JJ, Hesselink DA, Akin S, Struijs A, Birim O, Ince C, Manintveld OC, Caliskan K: Preoperative right heart hemodynamics predict postoperative acute kidney injury after heart transplantation. *Intensive Care Med* 2018; 44:588–97
121. Fortrie G, Manintveld OC, Caliskan K, Bekkers JA, Betjes MGH: Acute Kidney Injury as a Complication of Cardiac Transplantation. *Transplantation* 2016; 100:1740–9
122. Boyle JM, Moualla S, Arrigain S, Worley S, Bakri MH, Starling RC, Heyka R, Thakar CV: Risks and Outcomes of Acute Kidney Injury Requiring Dialysis After Cardiac Transplantation. *Am J Kidney Dis* 2006; 48:787–96
123. Jentzer JC, Bihorac A, Brusca SB, Rio-Pertuz GD, Kashani K, Kazory A, Kellum JA, Mao M, Moriyama B, Morrow DA, Patel HN, Rali AS, Diepen S van, Solomon MA, Council CCCWG of the HF and TSL: Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome JACC Council Perspectives. *J Am Coll Cardiol* 2020; 76:1084–101
124. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EAM, Zuckermann A, Councils on behalf of the IS for HLT (ISHLT) ID Pediatric and Heart Failure and Transplantation: The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. *J Heart Lung Transplant* 2016; 35:1–23
125. Lopez MG, Shotwell MS, Morse J, Liang Y, Wanderer JP, Absi TS, Balsara KR, Levack MM, Shah AS, Hernandez A, Billings FT: Intraoperative venous congestion and acute kidney injury in cardiac surgery: an observational cohort study. *Brit J Anaesth* 2021; 126:599–607
126. Gambardella I, Gaudino M, Ronco C, Lau C, Ivascu N, Girardi LN: Congestive kidney failure in cardiac surgery: the relationship between central venous pressure and acute kidney injury. *Interact Cardiovasc Th* 2016; 23:800–5
127. Kolsrud O, Karason K, Holmberg E, Ricksten S-E, Felldin M, Samuelsson O, Dellgren G: Renal function and outcome after heart transplantation. *J Thorac Cardiovasc Surg* 2018; 155:1593-1604.e1
128. Joannidis M, Druml W, Forni LG, Groeneveld ABJ, Honore PM, Hoste E, Ostermann M, Straaten HMO, Schetz M: Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017. *Intensive Care Med* 2017; 43:730–49
129. Meersch M, Schmidt C, Hoffmeier A, Aken HV, Wempe C, Gerss J, Zarbock A: Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. *Intensive Care Med* 2017; 43:1551–61
130. Vest AR, Chan M, Deswal A, Givertz MM, Lekavich C, Lennie T, Litwin SE, Parsly L, Rodgers JE, Rich MW, Schulze PC, Slader A, Desai A: Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. *J Card Fail* 2019; 25:380–400
131. Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, Hiesmayr M, Mayer K, Montejo JC, Pichard C, Preiser J-C, Zanten ARH van, Oczkowski S, Szczeklik W, Bischoff SC: ESPEN guideline on clinical nutrition in the intensive care unit. *Clin Nutr* 2019; 38:48–79

132. Piton G, Gouge AL, Boisramé-Helms J, Anguel N, Argaud L, Asfar P, Botoc V, Bretagnol A, Brisard L, Bui H-N, Canet E, Chatelier D, Chauvelot L, Darmon M, Das V, Devaquet J, Djibré M, Ganster F, Garrouste-Orgeas M, Gaudry S, Gontier O, Groyer S, Guidet B, Herbrecht J-E, Hourmant Y, Lacherade J-C, Letocart P, Martino F, Maxime V, Mercier E, Mira J-P, Nseir S, Quenot J-P, Richecoeur J, Rigaud J-P, Roux D, Schnell D, Schwebel C, Silva D, Sirodot M, Souweine B, Thieulot-Rolin N, Tinturier F, Tirot P, Thévenin D, Thiéry G, Lascarrou J-B, Reignier J, group CR in IC and S (CRICS): Factors associated with acute mesenteric ischemia among critically ill ventilated patients with shock: a post hoc analysis of the NUTRIREA2 trial. *Intensive Care Med* 2022; 48:458–66
133. Jin X, Wang J, Ma Y, Li X, An P, Wang J, Mao W, Mu Y, Chen Y, Chen K: Association Between Perioperative Glycemic Control Strategy and Mortality in Patients With Diabetes Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis. *Front Endocrinol* 2020; 11:513073

Legends to figures

Figure 1: Summary of the management of the heart transplant patient over time.
ICU: intensive care unit, CO: cardiac output, TTE: trans-thoracic echocardiography, TEE: trans-esophageal echocardiography, VTE: venous thromboembolism

Supplemental Digital Content 1: Suggestion of summarized postoperative shock assessment and management.

^a usually not found in vasoplegic syndrome characterized by warm extremities, normal capillary refill time and preserved Cardiac Index

^b In addition, right ventricle failure management include preservation of coronary blood flow via systemic blood pressure maintenance, preload optimization and avoidance of pulmonary vasoconstriction via ventilation settings

^c Epinephrine, Angiotensine II or Methylene Blue (single dose) might be considered in refractory vasodilatory shock, but the level of evidence is low.

CI: Cardiac Index, ECMO: ExtraCorporeal Membrane Oxygenation, MAP: Mean Arterial Pressure, NO: Nitric Oxide, PAC: Pulmonary Artery Catheter, PiCCO: Pulse Contour Cardiac Output, RVAD: Right Ventricular Assist Device, SBP: Systolic Blood Pressure, TTE: TransThoracic Echocardiography, TEE: TransEsophageal Echocardiography

Supplemental Digital Content 2: Suggested perioperative bleeding management protocol.

^a The neutralization of P2Y₁₂ inhibitors requires higher platelet concentrates dose ($\geq 2 \times$ standard dose). Platelet transfusion is unable to neutralize ticagrelor when the last intake is less than 24 hours.

^b Platelet transfusion may be indicated despite platelet count > 100 G/L if there is a known exposure to platelet inhibitors (especially P2Y₁₂ inhibitors) and/or platelet dysfunction diagnosed using laboratory or point-of-care platelet function tests.

ICU: intensive care unit, iCa^{2+} : ionized calcium, Hb: hemoglobin, CTR: clot time ratio, FCS: fibrinogen contribution to clot stiffness, PCS: platelet contribution to clot stiffness, CTH: heparinase clot time, CT_{IN}: INTEM clotting time, CT_{HEP}: HEPTTEM clotting time, A_{10FIB}: FIBTEM amplitude after 10 minutes, A_{10EXT}: EXTEM amplitude after 10 minutes, C_{EXT}: EXTEM clotting time, R_{CKH}: citrated kaolin with heparinase reaction time, R_{CK}: citrated kaolin reaction time, MA_{CFE}: citrated functional fibrinogen maximum amplitude, MA_{CRT}: citrated rapidTEG[®] maximum amplitude, R_{CKH}: citrated kaolin with heparinase reaction time, UFH: unfractionated heparin, INR: international normalized

ratio, DDAVP: deamino D-arginine vasopressin, VWF: von Willebrand factor, ECMO: extracorporeal membrane oxygenation, LVAD: left ventricular assist device.